Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026
Palisade Bio announced that data from its lead candidate, PALI-2108, a novel oral PDE4 inhibitor prodrug targeting the ileum and colon, will be presented at Digestive Disease Week 2026. The Phase 1 study data demonstrates rapid clinical, histologic, and biomarker improvements in ulcerative colitis patients. The company is progressing towards a Phas…